$-0.75 EPS Expected for Reata Pharmaceuticals, Inc. (RETA)

July 14, 2018 - By Hannah Black

Analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report $-0.75 EPS on August, 13.They anticipate $0.23 EPS change or 44.23 % from last quarter’s $-0.52 EPS. After having $0.15 EPS previously, Reata Pharmaceuticals, Inc.’s analysts see -600.00 % EPS growth. The stock increased 2.11% or $0.87 during the last trading session, reaching $42.2. About 348,671 shares traded or 53.98% up from the average. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has risen 19.31% since July 14, 2017 and is uptrending. It has outperformed by 6.74% the S&P500.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $1.10 billion. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreich's ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

More notable recent Reata Pharmaceuticals, Inc. (NASDAQ:RETA) news were published by: Seekingalpha.com which released: “Reata Pharma: This TPT Watchlist Stock Is Doing Pretty Well” on June 18, 2018, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data” published on June 22, 2018, Nasdaq.com published: “Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of …” on July 10, 2018. More interesting news about Reata Pharmaceuticals, Inc. (NASDAQ:RETA) were released by: Globenewswire.com and their article: “Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility” published on June 14, 2018 as well as Nasdaq.com‘s news article titled: “Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR?t” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.